SCHEMBL5256159

SCHEMBL5256159

CCCCCCN(C)CCNC=O

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 3/20 0.65
ADH1A P07327 3/20 0.65
ADH7 P40394 3/20 0.65
ADH1C P00326 2/20 0.65
EPHX1 P07099 1/20 0.65
ADH4 P08319 1/20 0.65
S1PR2 O95136 1/20 0.47
S1PR1 P21453 1/20 0.47
S1PR3 Q99500 1/20 0.47
S1PR5 Q9H228 1/20 0.47
KDM5A P29375 4/20 0.44
KDM4C Q9H3R0 3/20 0.44
PHF8 Q9UPP1 2/20 0.44
DNM1 Q05193 3/20 0.43
TSHR P16473 2/20 0.41
KDM5C P41229 1/20 0.41
KDM5B Q9UGL1 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GGPS1 O95749 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22996894 0.85 ADH1B (0.52) ADH1BADH1AADH7ADH1CEPHX1
SCHEMBL25914078 0.83 ALDH1A1 (0.62) ADH1BADH1AADH7ADH1CEPHX1
SCHEMBL18173957 0.83 ALDH1A1 (0.62) ADH1BADH1AADH7ADH1CEPHX1
SCHEMBL31325292 0.83 ALDH1A1 (0.62) ADH1BADH1AADH7ADH1CEPHX1
SCHEMBL670190 0.83 ALDH1A1 (0.62) ADH1BADH1AADH7ADH1CEPHX1
SCHEMBL29037600 0.82 ADH1A (0.63) ADH1BADH1AADH7ADH1CEPHX1
SCHEMBL27269307 0.82 ADH1A (0.63) ADH1BADH1AADH7ADH1CEPHX1
SCHEMBL18034255 0.81 DNM1 (0.48) ADH1BADH1AADH7ADH1CEPHX1
SCHEMBL21498012 0.81 ALDH1A1 (0.59) ADH1BADH1AADH7ADH1CEPHX1
SCHEMBL18034254 0.81 DNM1 (0.48) ADH1BADH1AADH7ADH1CEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3778571-A1 (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE Bioway, Inc. (KR) 2021-02-17 EP disclosed
EP-1221440-B1 Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators OTSUKA PHARMA CO LTD (JP) 2007-04-25 EP disclosed
US-6642223-B2 A benzoazepin or benzodiazepin derivatives, shows excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as antagonist OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2003-11-04 US disclosed
EP-0765314-B1 BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS OTSUKA PHARMA CO LTD (JP) 2003-05-07 EP disclosed
EP-1221440-A1 Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators Otsuka Pharmaceutical Company, Limited (JP) 2002-07-10 EP disclosed
US-20020049194-A1 Benzoheterocyclic derivatives OGAWA HIDENORI (JP) 2002-04-25 US disclosed
US-6335327-B1 Benzoheterocyclic derivatives OTSUKA PHARMACEUTICALS CO., LTD. (JP) 2002-01-01 US disclosed
US-6096735-A Benzoheterocyclic derivatives OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 2000-08-01 US disclosed
EP-0765314-A1 BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-04-02 EP disclosed
WO-1995034540-A1 BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1995-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049194-A1 Benzoheterocyclic derivatives AVPR2, AVPR1A, AVPR1B ADH1B 2882/4885ADH1A 318/4885ADH7 2087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.